Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 8-K (Current Report)
Report Date: May 12, 2026
Reporting Period: First Quarter ended March 31, 2026
Business Context: The Company announced its financial results for the first quarter of 2026 via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a notification of the results and incorporates the press release by reference. The filing text does not provide specific numerical values for the following metrics:
- Revenue
- Profit (Net Income/Loss)
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The Form 8-K text does not include specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. These disclosures are contained within the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 12, 2026) for actual Q1 2026 financial figures.
- Verify year-over-year revenue and net income trends in the press release.
- Check the press release for updated cash runway or liquidity guidance.
- Confirm any new operational milestones or clinical trial updates mentioned in the full press release.